Risk factors associated with postoperative adjuvant therapy for resectable esophageal squamous cell carcinoma
- VernacularTitle:可切除食管鳞癌术后辅助治疗相关危险因素的研究进展
- Author:
Teng ZENG
1
,
2
;
Rui HE
1
;
Xiaobo CHEN
1
;
Chao MING
1
;
Guangqiang ZHAO
1
Author Information
1. Department of Thoracic Surgery Ⅰ, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, 650118, P. R. China
2. Department of Thoracic Surgery, Northeast Yunnan Central Hospital, Zhaotong, 657000, Yunnan, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal squamous cell carcinoma;
adjuvant therapy;
risk factors;
lymph node metastasis;
prognosis;
individualized therapy;
molecular biomarker;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(02):326-332
- CountryChina
- Language:Chinese
-
Abstract:
The benefit of postoperative adjuvant therapy for patients with resectable esophageal squamous cell carcinoma (ESCC) is not yet supported by high-level evidence. This review analyzes the role of adjuvant therapy by examining the discrepancy between clinical needs and guidelines, its historical evolution, recent advances in high-risk factors, and future outlooks. We provide a detailed discussion of high-risk factors used for patient selection, including lymph node positivity, and for node-negative patients, features such as tumor length, location, T stage, extent of lymph node dissection, differentiation, vascular and neural invasion, laboratory indices, and molecular markers. The goal is to inform the development of individualized precision treatment strategies for resectable ESCC.
